logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
Showing 1 - 20 of 23 Items
Showing 1 - 20 of 23 Items
Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.
  • Current Page (20)
  • CSV
  • BibTeX
  • EndNote
  • All Results (23)
  • CSV
  • BibTeX
  • EndNote
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Characterizing treatment adherence trajectories in the endTB multisite cohort of drug-resistant tuberculosis patients: an application of group-based trajectory modelling

Law S, Fulcher I, Ashraf S, Bastard M, Docteur W,  et al.
2025-08-22 • Clinical Infectious Diseases
2025-08-22 • Clinical Infectious Diseases

BACKGROUND

In tuberculosis (TB) care, adherence is often assessed using a simple 80% threshold, ...

Journal Article
|
Review
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Conference Material
|
Slide Presentation
Conference Material
|
Abstract
Journal Article
|
Research
Journal Article
|
Letter

Association of smoking and alcohol use with rifampin-resistant TB treatment outcomes

Campbell JR, Chan ED, Anderson LF, Bonnet M, Brode SK, 
Journal Article
|
Commentary
Journal Article
|
Commentary
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Review
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research

Management of individuals exposed to multidrug-resistant or rifampicin-resistant tuberculosis

Seddon JA, Achar J, Malik AA, Hughes J, Burzynski J,  et al.
2025-06-06 • Lancet Infectious Diseases
2025-06-06 • Lancet Infectious Diseases

The effectiveness and safety of bedaquiline, pretomanid, and linezolid (BPaL)-based regimens for rifampicin-resistant tuberculosis in non-trial settings - A prospective cohort study in Belarus and Uzbekistan

Sinha A, Klebe R, Rekart ML, Alvarez JL, Skrahina A,  et al.
2025-02-18 • Clinical Infectious Diseases
2025-02-18 • Clinical Infectious Diseases

BACKGROUND

Only 63% of patients initiating multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment in 2020 were treated successfully. 24-Wee...

Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis

Garcia-Prats AJ, Garcia-Cremades M, Cox V, Kredo T, Dunbar R,  et al.
2025-02-01 • Lancet Child and Adolescent Health
2025-02-01 • Lancet Child and Adolescent Health

BACKGROUND

There are few data on the treatment of children and adolescents with multidrug-resistant (MDR) or rifampicin-resistant (RR) tuberculosis, especially ...

Supporting multidrug-resistant or rifampicin-resistant TB treatment adherence in people with harmful use of alcohol through person-centred care

Harrison RE, Shyleika V, Vishneuski R, Leonovich O, Vetushko D,  et al.
2024-11-06 • Oxford Medical Journal
2024-11-06 • Oxford Medical Journal

BACKGROUND

TB is concentrated in populations with complex health and social issues, including alcohol use disorders (AUD). We describe treatment adherence and o...

Standards for clinical trials for treating TB

du Cros PAK, Greig J, Cross GB, Cousins C, Berry C,  et al.
2023-12-01 • International Journal of Tuberculosis and Lung Disease
2023-12-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
The value, speed of completion and robustness of the evidence generated by TB treatment trials could be improved by implementing standards for best practice.

METH...

Clinical standards for drug-susceptible TB in children and adolescents

Chiang SS, Graham SM, Schaaf HS, Marais BJ, Sant’Anna CC,  et al.
2023-08-01 • International Journal of Tuberculosis and Lung Disease
2023-08-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
These clinical standards aim to provide guidance for diagnosis, treatment, and management of drug-susceptible TB in children and adolescents.

METHODS
Fifty-tw...

Preliminary data on safety and effectiveness of six-month all-oral regimens in patients with rifampicin-resistant tuberculosis in Belarus

Yatskevich N, Hurevich H, Solodovnikova V, Garsevanidze E, Lachenal N,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023

Preliminary data on safety and effectiveness of six-month all-oral regimens in patients with rifampicin-resistant tuberculosis in Belarus

Yatskevich N, Hurevich H, Solodovnikova V, Garsevanidze E, Lachenal N,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
INTRODUCTION
The total duration of treatment for rifampicin-resistant tuberculosis (RR-TB) in Belarus prior to December 2022 was 18-20 months. The efficacy of treatment with such reg...

Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications

Rich ML, Khan UT, Zeng C, LaHood AN, Franke MF,  et al.
2023-06-01 • International Journal of Tuberculosis and Lung Disease
2023-06-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
Evidence of the effectiveness of the WHO-recommended design of longer individualized regimens for multidrug- or rifampicin-resistant TB (MDR/RR-TB) is limited.

OB...
et al.
2023-04-01 • International Journal of Tuberculosis and Lung Disease
2023-04-01 • International Journal of Tuberculosis and Lung Disease

Caring for adolescents and young adults with tuberculosis or at risk of tuberculosis: Consensus statement from an international expert panel

Chiang SS, Waterous PM, Atieno VF, Bernays S, Bondarenko Y,  et al.
2023-03-01 • Journal of Adolescent Health
2023-03-01 • Journal of Adolescent Health

Clinical perspectives on treatment of rifampicin-resistant/multidrug-resistant TB

Cox V, McKenna L, Acquah R, Reuter A, Wasserman S,  et al.
2020-11-01 • International Journal of Tuberculosis and Lung Disease
2020-11-01 • International Journal of Tuberculosis and Lung Disease
Rapid diagnostics, newer drugs, repurposed medications, and shorter regimens have radically altered the landscape for treating rifampicin-resistant TB (RR-TB) and multidrug-resistant TB ...

High time to use rapid tests to detect multidrug resistance in sputum smear-negative tuberculosis in Belarus

Rusovich V, Kumar AMV, Skrahina A, Hurevich H, Astrauko A,  et al.
2014-12-21 • Public Health Action
2014-12-21 • Public Health Action
SETTING
Belarus (Eastern Europe) is facing an epidemic of multidrug-resistant tuberculosis (MDR-TB). In 2012, rapid molecular diagnostics were prioritised for sputum smear-positive p...

Poor treatment outcomes among multidrug-resistant tuberculosis patients in Gomel Region, Republic of Belarus

Khaliaukin A, Kumar AMV, Skrahina A, Hurevich H, Rusovich V,  et al.
2014-10-21 • Public Health Action
2014-10-21 • Public Health Action
SETTINGS
Tuberculosis (TB) health facilities in the Gomel Region, Republic of Belarus-settings with a high burden of multidrug-resistant TB (MDR-TB) and human immunodeficiency virus ...

New and repurposed drugs for pediatric multidrug-resistant tuberculosis. Practice-based recommendations

Harausz EP, Garcia-Prats AJ, Seddon JA, Schaaf HS, Hesseling AC,  et al.
2016-11-17 • American Journal of Respiratory and Critical Care Medicine
2016-11-17 • American Journal of Respiratory and Critical Care Medicine
It is estimated that 33,000 children develop multidrug-resistant tuberculosis (MDR-TB) each year. In spite of these numbers, children and adolescents have limited access to the new and r...

MDR/XDR-TB management of patients and contacts: challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network

Migliori GB, Tiberi S, Zumla A, Petersen E, Chakaya JM,  et al.
2020-02-01 • International Journal of Infectious Diseases
2020-02-01 • International Journal of Infectious Diseases
The continuous flow of new research articles on MDR-TB diagnosis, treatment, prevention and rehabilitation requires frequent update of existing guidelines. This review is aimed at provid...

Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis

Harausz EP, Garcia-Prats AJ, Law S, Schaaf HS, Kredo T,  et al.
2018-07-11 • PLOS Medicine
2018-07-11 • PLOS Medicine
An estimated 32,000 children develop multidrug-resistant tuberculosis (MDR-TB; Mycobacterium tuberculosis resistant to isoniazid and rifampin) each year. Little is known about the optima...

Clinical standards for the diagnosis, treatment and prevention of TB infection

Migliori GB, Wu SJ, Matteelli A, Zenner D, Goletti D,  et al.
2022-03-01 • International Journal of Tuberculosis and Lung Disease
2022-03-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
Tuberculosis (TB) preventive therapy (TPT) decreases the risk of developing TB disease and its associated morbidity and mortality. The aim of these clinical standards is t...

Off-label use of bedaquiline in children and adolescents with multidrug-resistant tuberculosis

Achar J, Hewison CCH, Cavalheiro AP, Skrahina A, Cajazeiro J,  et al.
2017-10-01 • Emerging Infectious Diseases
2017-10-01 • Emerging Infectious Diseases
We describe 27 children and adolescents <18 years of age who received bedaquiline during treatment for multidrug-resistant tuberculosis. We report good treatment responses and no cessati...